Market Research Future published a Half Cooked Research Report on “Global Blood Transfusion Diagnostics Market Research Report-Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.
Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S), Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens (Germany), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).are some of the prominent players at the forefront of competition in the global Blood Transfusion Diagnostics market and top seven players are profiled in MRFR Analysis.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1126
Global Blood Transfusion Diagnostics Market - Overview
Blood transfusion is an essential part of providing healthcare services to the patients. Blood and blood products like RBC’s, WBC’s, platelets and others are transfused from one person to another. This requires screening tests which are vital before conducting blood transfusion. Strict regulation governing the use and transfer of blood, increasing awareness regarding blood transfusion and automation of blood banks drive the growth of this market. Furthermore, increasing demand for diagnostic and treatment devices in developed and developing countries further influence the growth of the market. However, the growth of the market is restrained by various factors such as risk involved in transmission of infectious disease from one person to another without carrying out screening procedure.
Global Blood Transfusion Diagnostics Market - Competitive Analysis
There is a significant increase in the number of the company offering blood transfusion diagnostics. Some major companies are trying to focus on new and advanced tests & products to gain the market. Whereas, some are has used the technique of acquisition and collaboration to gain the blood transfusion diseases market.
Hoffmann-La Roche AG:
- August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholders USD 190 million upfront and up to USD 235 million in contingent product related milestones
- February 2015 : F. Hoffmann-La Roche AG announced the collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing
- September 2014: F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy
Abbott:
- June, 2017: Alere shareholders approve amended merger with Abbott. This merger will further strengthen the global presence of the company.
- August, 2016: Abbott announced the introduction of its new “Alinity”, a family of next generation systems across immunoassay, clinical chemistry, point of care, haematology, blood and plasma screening and molecular diagnostics.
- April, 2016: The company received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.
- April, 2016: Abbott received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia. The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.
Bio-Rad Laboratories, Inc.:
July 2017: Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products launched Amplichek I quality control for the testing of infectious diseases.
Global Blood Transfusion Diagnostics Market - Regional Analysis
Globally, Americas account for the largest market share in blood transfusion diagnostics market consists of two regions namely North America and South America. Increasing in number of blood banks, adoption of automation in blood banks, awareness programs in school & medical institutes and demand of safe and reliable technology for blood transfusion drive this market in North America. Increasing adoption of Nucleic Acid Amplification for diagnosis of blood and blood products also contribute to the growth of this market in North America. United States is the biggest market place worldwide contributing 46% of total blood transfusion diagnostics market. Ortho-Clinical Diagnostic is the largest transfusion diagnostic equipment and solution provider with estimated market share of 7 to 8%. Medical institutes conduct lecture and conference on safe blood transfusion for medical students and also for patients. Europe blood transfusion diagnostics market has observed stable growth owing to increasing demand for advanced diagnostic products. Asia-Pacific is fastest growing market region for this market due to presence of huge patient pool, and huge opportunity for the market growth. The Middle East and Africa holds the least share in the market due to lack of awareness among the people and limited development of medical sector.
FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/blood-transfusion-diagnostics-market-1126
Global Blood Transfusion Diagnostics Market Information, by product (Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations, others) by Technology (Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test, others) by end user (Hospitals, Clinics, Blood banks, Laboratories) - Forecast till 2027Ortho Clinical Diagnostics (U.S), Immucor (U.S), Beckman Coulter (U.S), Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens (Germany), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).are some of the prominent players at the forefront of competition in the global Blood Transfusion Diagnostics market and top seven players are profiled in MRFR Analysis.
However, the growth of the market is restrained by various factors such as risk involved in transmission of infectious disease from one person to another without carrying out screening procedure.Global Blood Transfusion Diagnostics Market - Competitive AnalysisThere is a significant increase in the number of the company offering blood transfusion diagnostics.
Some major companies are trying to focus on new and advanced tests & products to gain the market.
Whereas, some are has used the technique of acquisition and collaboration to gain the market.Hoffmann-La Roche AG:August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics.
This merger will further strengthen the global presence of the company.August, 2016: Abbott announced the introduction of its new “Alinity”, a family of next generation systems across immunoassay, clinical chemistry, point of care, haematology, blood and plasma screening and molecular diagnostics.April, 2016: The company received FDA approval for its companion diagnostics “Vysis CLL FISH probe kit” in Leukemia.
The kit is used to detect the 17p deletion in chronic lymphocytic leukemia patients, the target population of a new drug from AbbVie.Bio-Rad Laboratories, Inc.:July 2017: Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products launched Amplichek I quality control for the testing of infectious diseases.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/1126Global Blood Transfusion Diagnostics Market - Regional AnalysisGlobally, America’s account for the largest market share in blood transfusion diagnostics market consists of two regions namely North America and South America.
While IVF or In-vitro fertilization is a blessing from medical science for women with age or health issues, it is still a risky treatment that can cause negative outcomes.
Egg donor IVF is presented as a last resort to couples by experts as an alternative to enjoy parenthood where there is no other way.
So, how to choose the right egg donor for your IVF?Today, women who face fertility issues that hinder the process of conceiving naturally, approach an IVF Specialists to assist their journey to become a mother.
However, in some cases, self-egg IVF is not an appropriate option due to decreasing egg reserve or unfavorable age in spite of egg reserve, the egg donor is recommended.The experts, then, counsel the couple about this third-party reproduction, in which, there is no direct contact with donors, their images are not shared, and their anonymity is maintained.
While donors do not have an idea about who will be receiving their eggs, intended mothers also do not know about the donor.
There are many aspects to consider while selecting who feels right and what meets the requirements for you in this beautiful process of creating your family.
The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.
The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.
Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnosticsDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589Global Market Segmentation:The market is broadly segmented into assays, kits, & reagents; instruments; and services & software based on product & service.
The assays, kits, & reagents segment accounted for the largest share of the global market and is expected to register the highest CAGR during the forecast period.
The increasing number of infectious disease diagnostic tests carried out; easy accessibility to a wide range of reagents; and the growing need for reliable, specific, and faster detection of infectious diseases in the early stages are the key factors driving the IDD assays, kits, & reagents market.Based on the disease type, the market is segmented into hepatitis, HIV, HAIs, CT/NG, HPV, TB, Influenza, and other diseases.
The hepatitis diagnostics segment accounted for the largest share of the global market in 2017.
